MAP2K7 and melanoma: A study of adjuvant combination therapy with BRAF inhibitor, dabrafenib, and MEK inhibitor, trametinib, in patients with resected stage III BRAF V600E/K-mutant melanoma showed improved recurrence free survival benefit at 3 years with overall survival rate of 86% compared to 77% with placebo.